CombiMatrix Corp.

2024年4月24日，美国基因检测公司Invitae发布公告，宣布与美国综合检测领域的巨头Labcorp达成了业务出售协议。Labcorp将以2.39亿美元的现金收购Invitae现有的资产，并且承接所有的客户、合作伙伴以及员工。该笔收购预计2024年第三季度完成。崛起的辉煌Invitae公司最初于2010年作为Genomic Health的子公司成立，并在2012年被分拆出来独立运营。Invitae最初主要专注于遗传病的诊断检测，获得了认可之后将其服务扩展到了更广泛的基因检测和咨询服务。2015年，Invitae成功在纽交所IPO，筹集了大量资金后，Invitae开始通过收购基因检测公司，不断扩展自己的基因检测业务范围。2017年，Invitae收购了Good Start Genetics和CombiMatrix。2020年，14亿美元收购ArcherDX。2021年，3.25亿美元收购了Ciitizen。这些收购业务逐渐扩大了Invitae的业务范围，提升了在基因检测领域的市场地位以及影响力，随之，Invitae也吸引到孙正义旗下软银子公司的注意。2021年4月，Invitae获得软银高达11.5亿美元（可转换债形式、2028年到期）的巨额投资，这一轮融资使Invitae的市值一度高达77亿美元。获得大笔的资金之后，Invitae进一步发展了基因检测业务，延续了先前的收购战术。2021年4月，1.2亿美元收购Genosity。2021年9月，以1.25亿美元收购Citizen。财务数据暗藏危机翻看财务数据，这几年来，Invitae的营收取得稳步增长，2019年-2022年，Invitae总营收分别为2.17亿美元、2.80亿美元、4.60亿美元、5.16亿美元，同比分别增长46.8%、28.85%、64.68%。然而，Invitae却从未在任一财年获得盈利，一直处于亏损状态。2022年，因商誉减值，公司录得高达31.06亿美元的净亏损，同比2021年（-3.79亿美元）扩大亏损近9倍。直到最后一次公布财报（2023Q3），Invita公司累计产生的亏损达到61.7亿美元。连年亏损所带来的财务压力，迫使不得Invitae不展开自救。2022年，Invitae启动了一项重组计划，采取了大规模的裁员、出售非核心业务等一系列自救措施，旨在将年度开支缩减约3.26亿美元。2022年12月20日，Invitae将Archer NGS检测业务出售给Danaher旗下的IDT。2023年12月13日，Invitae剥离Ciitizen健康数据平台。2024年1月22日，Invitae宣布NIPT业务出售给Natera。然而，这些努力最终未能扭转公司的破产命运，出售资产所回笼的资金远远无法填补公司巨额的亏空。2024年2月13日，Invitae申请了破产保护。根据提交法院的申请破产文件，Invitae预计股东在公司破产过程中无法回收资金，公司总资产价值在5亿至10亿美元之间，大约将欠债15亿美元。Invitae的股价已经从最高时的60美元跌至如今的0.02美元，相应地，市值从 2020年的70亿美元降至500多万美元左右。参考出处：医学遗传学巨头Invitae可能申请破产https://www.genomeweb.com/business-news/invitae-stock-tumbles-rumors-impending-bankruptcy-filing本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处········

BANGALORE, India, Jan. 10, 2024 /PRNewswire/ -- Preimplantation Genetic Testing - Global Market Insights and Sales Trends 2024 is Segmented by Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), by Application (Air Splicing Bus Duct (BMC), Intensive Insulation Plug Bus Duct (CMC), Higher Strength Enclosed Bus Duct (CFW)): Global Opportunity Analysis and Industry Forecast, 2023-2029. It is Published in Valuates Reports Under the Category of Medical Devices & Equipment. The Global Preimplantation Genetic Testing Market Size is expected to reach USD 528.9 Million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. Claim Your Free Sample Now: Major Factors driving the growth of Preimplantation Genetic Testing Market There is a greater need for PGT as a result of expanding acceptance of in vitro fertilization (IVF), an increase in the frequency of reproductive issues brought on by postponed motherhood, and more knowledge of genetic abnormalities. PGT is more appealing and accessible thanks to technological developments in genetic screening methods, growing healthcare infrastructure, and integrated personalized treatment. Unlock Insights: View Full Report Now! TRENDS INFLUENCING THE GROWTH OF PREIMPLANTATION GENETIC TESTING MARKET Global genetic problem prevalence is a major factor propelling the PGT market's expansion. The demand for PGT as a preventive strategy has increased as couples want to ensure healthy pregnancies and are increasingly aware of their genetic risks. PGT offers a way to recognise inherited illnesses and prevent them from being passed onto future generations. The issues associated with fertility are partly caused by the tendency towards delayed motherhood and the ensuing rise in maternal age. The chance of chromosomal abnormalities in embryos increased with mother age. PGT becomes an essential tool for older couples and those experiencing infertility since it allows embryos with normal genetic profiles to be chosen for implantation. Technological developments in genetic screening have improved PGT's accuracy and efficiency considerably. Examples of these developments include next-generation sequencing and microarray analysis. The industry is growing as a result of these technical advancements since they offer more thorough genetic information and increase confidence in the selection of viable embryos. The need for PGT is driven by the growing acceptance and accessibility of in vitro fertilization (IVF) treatments on a global scale. The market is further driven ahead by the addition of PGT as a supplementary technique to safeguard the health of embryos, as IVF becomes a more common option for infertile couples. Growth in the market is facilitated by advancements in PGT alternatives and healthcare infrastructure, particularly in emerging economies. A favorable atmosphere for market expansion is created by educating potential parents about the advantages of PGT through educational programmes and counseling services. One significant motivator is the incorporation of genetic counseling and personalized medication within the PGT procedure. The market demand for PGT is further stimulated by enhancing its overall attractiveness and efficacy through the provision of complete counseling services and customisation of genetic testing to unique patient profiles. Own It Today – Buy Now! PREIMPLANTATION GENETIC TESTING MARKET SHARE In terms of market share, North America led the way in preimplantation genetic testing worldwide in 2017. Europe came in second. The significant adoption of genomic techniques, the growing number of IVF procedures (with declining fertility rates), and the continuous trend of replacing conventional genomic technologies with cutting-edge and novel genetic techniques (like FISH and NGS) are the main causes of the large share in the North American region. Because of the increased attention that companies are paying to emerging markets and the advancements made in the healthcare infrastructure in these areas, the Asia-Pacific region is anticipated to grow at the fastest rate throughout the projection period. Purchase Regional Report: Key Players: Illumina Inc Thermo Fisher Agilent Technologies PerkinElmer Inc CooperSurgical Abbott Laboratories Natera Rubicon Genomics Oxford Gene Technology Yikon Genomics Scigene Beijing Genomics Institute Good Start Genetics Invicta Genetics Genea Limited Progenesis CombiMatrix Purchase Chapters: SUBSCRIPTION We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans. DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS! - In Vitro Fertilization Test Market - Preimplantation Genetic Testing Kits (PGT Kits) Market - Direct-to-consumer Genetic Testing Market revenue was USD 1328 Million in 2022 and is forecast to a readjusted size of USD 4521.7 Million by 2029 with a CAGR of 18.9% during the review period (2023-2029). - Non-invasive Preimplantation Genetic Testing Market - Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market - Preimplantation Genetic Testing for Aneuploidy Kits Market - Non-invasive Preimplantation Genetic Testing Market - DTC Genetic Testing Market - IVF Market - Nephro Genetic Testing market is projected to reach USD 547.2 Million in 2029, increasing from USD 353 Million in 2022, with the CAGR of 6.5% during the period of 2023 to 2029. - The genetic testing market accounted for USD 12,682 Million in 2019, and is expected to reach USD 21,260 Million by 2027, registering a CAGR of 10.1%. - The global epigenetics market was valued at USD 772 Million in 2019, and is projected to reach USD 2,168 Million by 2027, registering a CAGR of 13.6%. - Animal Genetics market size will reach USD 8675.8 Million in 2028, growing at a CAGR of 7.8% over the analysis period. - Pediatric Genetic Testing Market - Newborn and Prenatal Genetic Testing Market - Human Genetics Market - At-home Genetic Testing Market - Bioinformatics Market Size is USD 8,614.29 Million in 2019, and is projected to reach USD 24,731.61 Million by 2027, growing at a CAGR of 13.4%. - Predictive Genetic Testing And Consumer & Wellness Genomics Market - Pet Genetic Testing market is projected to reach USD 302.3 Million in 2029, increasing from USD 164.1 Million in 2022, with the CAGR of 8.4% during the period of 2023 to 2029. - Weight Management Genetic Testing Market - Pet DNA Testing Market - Horse DNA Testing Market - Animal DNA Testing Market - Consumer Grade Genetic Testing market is projected to reach USD 4031.4 Million in 2029, increasing from USD 2633 Million in 2022, with a CAGR of 6.0%. - Non-Invasive Prenatal Testing market size is expected to reach USD 10060 Million by 2029, growing at a CAGR of 10.7% from 2023 to 2029. - DNA Test for Dogs market is projected to grow from USD 143.5 Million in 2023 to USD 281.7 Million by 2029, at a Compound Annual Growth Rate (CAGR) of 11.9% during the forecast period. - Pre-marital and Pre-Pregnancy Genetic Testing Service Market - Fragile X Syndrome Genetic Testing Market - Non-invasive Prenatal Genetic Screening Test Kits market is projected to reach USD 374.9 Million in 2029, increasing from USD 267 Million in 2022, with a CAGR of 5.3% during the period of 2023 to 2029. - Pre-marital and Pre-Pregnancy Genetic Testing Service Market - Organ On Chip Market revenue was USD 88 Million in 2022 and is forecast to a readjusted size of USD 621.2 Million by 2029 with a CAGR of 31.2%. - Digital PCR Market - Digital Therapeutics Market - Medical Supplies Market - Disposable Medical Supplies Market DISCOVER OUR VISION: VISIT ABOUT US! Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs. Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs. To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources. YOUR FEEDBACK MATTERS: REACH OUT TO US! Valuates Reports [email protected] For U.S. Toll-Free Call 1-(315)-215-3225 WhatsApp: +91-9945648335 Website: Blog: Pinterest: Twitter: Facebook: Logo: SOURCE Valuates Reports

DUBLIN, Nov. 28, 2023 /PRNewswire/ -- The "Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's offering. The Global Preimplantation Genetic Testing (PGT) Market was valued at USD 557.28 million in 2022 and is projected to experience substantial growth, with a forecasted Compound Annual Growth Rate (CAGR) of 8.22% to reach USD 890.47 million by 2028. The report highlights key drivers, challenges, and trends shaping the global PGT market. The rising incidence of genetic disorders is a significant driver, with individuals and couples increasingly turning to PGT to reduce the risk of passing genetic disorders to their children. Advancements in genetic screening technologies enhance the accuracy and accessibility of PGT procedures, contributing to market growth. Additionally, the increasing demand for in vitro fertilization (IVF) procedures boosts the adoption of PGT services. Key Drivers: Rising Incidence of Genetic Disorders: The increasing occurrence of genetic disorders drives the demand for PGT, enabling couples with family histories or genetic mutations to identify unaffected embryos before implantation. Advancements in Genetic Screening Technologies: Technological innovations enhance the accuracy and efficiency of PGT, making it more accessible and feasible for a broader range of individuals and couples. Increasing Demand for IVF Procedures: The growing demand for IVF procedures significantly drives the adoption of PGT as it enhances the success rates of fertility treatments and ensures healthier pregnancies. Key Challenges: Ethical and Moral Concerns: The use of PGT for selecting specific traits raises ethical concerns about potential discrimination based on genetic makeup and moral questions about abortion in cases of genetic diseases. Inaccuracies and False Positives/Negatives: Inaccuracies in PGT can lead to the selection of embryos with genetic diseases or the discarding of healthy embryos, affecting the chances of a successful pregnancy. Limited Access and Awareness: PGT is relatively new, with availability varying by region. Limited access to PGT services and low awareness can be barriers for some individuals or couples. Key Trends: Growing Number of Fertility Clinics Offering PGT Services: The increasing number of fertility clinics providing PGT services expands access to genetic testing, making it more accessible to a broader population. Segmental Insights: Procedure Segment: Pre-implantation genetic diagnosis (PGD) dominates the procedure segment, used to identify specific genetic defects or chromosomal abnormalities in embryos before implantation. Product Segment: Reagents and consumables lead the product segment, providing essential components for conducting PGT procedures. Technology Segment: Polymerase chain reaction (PCR) technology dominates the PGT technology segment for its accuracy and sensitivity in genetic analysis. Application Segment: Aneuploidy screening is the leading application of PGT, helping fertility clinics select embryos with the correct chromosomal content. End-Use Segment: Hospitals are the primary end-use segment of the PGT market, attracting a high volume of patients seeking fertility treatments. Regional Insights: Europe: Europe leads the global PGT market due to well-developed healthcare systems, advanced medical facilities, and regulatory frameworks governing assisted reproductive technologies and genetic testing. Key Market Players: Several key players are highlighted in the report, including California Pacific Medical Center (CPMC) CombiMatrix CooperSurgical F. Hoffmann-La Roche Ltd. Genea Genesis Genetics Good Start Genetics IGENOMIX Illumina Invitae Laboratory Corporation of America Holdings The Global Preimplantation Genetic Testing (PGT) Market is poised for significant growth driven by the rising incidence of genetic disorders, advancements in genetic screening technologies, and the increasing demand for IVF procedures. Ethical and moral concerns, inaccuracies, and limited awareness pose challenges to market growth, but the growing number of fertility clinics offering PGT services expands access to genetic testing. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets